TF and cancer: These included 16 mutated sites with ChIP-sequencing evidence for CTCF/ZNF263 binding, indicating that the mutation may interfere with TF binding and regulatory activity, and encompassed cis-acting lncRNAs previously implicated in cancer, such as HOTAIRM1 (HOXA1-AS) [60], HOTTIP (HOXA13-BT) [61], ZEB1-AS [62] and ZEB2-AS [63, 64].